Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatm | Page 17

AUTHOR BIOS
Peter Langecker, MD, PhD
Executive Medical Director, Global Oncology; Clinipace Worldwide
Peter has more than 25 years of extensive hands-on experience in establishing
and conducting industry-sponsored oncology and hematology clinical research
and development according to GCP, GLP and GMP regulations. His primary
responsibilities at Clinipace Worldwide include the provision of internal and external
drug development, regulatory strategy and medical affairs consulting to Clinipace
project teams and clients. Peter’s medical training and published research is focused
on preclinical and clinical oncology and the hormonal regulation of breast cancer.
He is an author and co-author of more than 50 publications and posters.

Barb Geiger, BSN, RN
Executive Vice President of Clinical Operations, Clinipace Worldwide
Barb brings more than 25 years of experience in the conduct and management
of Phase I-IV clinical trials and in the evaluation and selection of global clinical
trial vendors. Prior to founding Worldwide Clinical Research (WWCR) in 2000,
she spent 10 years at global CROs. Additionally, Barb spent eight years at a major
pharmaceutical company and started her clinical research career in a Phase I/II
private research unit.

17